Agenda

All timings are in SGT (UTC +8). Click here to convert to your timezone »

Day 1: 3 November 2020

13:00
Chairperson’s Opening Remarks

Chen Guang, Consultant, Agency for Science, Technology and Research (A*STAR), Singapore


Joint Opening Plenary


13:10
Keynote Address:
China’s Big Leap towards BioPharma 2030  Innovation, Industrialization, Internationalization

Dr. Song Ru Lin, Executive President, China Pharmaceutical Innovation and Research Development Association (PhIRDA), China

13:30
Venture Capitals’ Roundtable:  
Show Me the Drug

  • Investment landscape in the Chinese biopharma market
  • Evaluating drug pipelines and development prospects
  • Mergers, expansion and JVs – Where do we see transactions picking up?
  • Financing new plants, new therapeutics, product launch and scaling-up operations – How do we review?
  • Manufacturing 4.0 – How do VCs and banks play a part in modernising the value chain?

Moderator:
Judith Li, Partner, Lilly Asia Ventures, China

Panelists:
Rani Jarkas, Chairman, Cedrus Group, Hong Kong
Lynn Yang, Managing Director, Sequoia Capital, China
Michael Xue, Managing Director, Morningside Ventures, China

14:15
Industry Spotlight:
Addressing Complex Protein Challenges with Lonza’s GS Xceed® Toolbox

Dr. Allison Porter, Head of Expression System Sciences, Lonza Pharma & Biotech, U.K.

14:45
Online Networking & Stretch Break


End of Joint Opening Plenary and 9th Annual Cell Line Development & Engineering Asia & 10th Annual Biomanufacturing commences

Innovative Bioprocess Development


15:00
Powder Handling and Hydration in Upstream Processes  

  • Evaluation of powder transfer bag designs for solid media and buffer handling
  • Trusted Weight Bags and streamlining incoming sampling requirements
  • Novel method for eliminating vortex mixing of powders
  • Supply chain security and supplier performance for a single use supplier

Scott Patterson, Vice President, Pharma / Biopharma, Technical Support, ILC Dover, Singapore

15:30
CMC development of Antibody Drug Conjugates

  • ADC introduction + ADC CMC challenge and approach

Dr. Huang Peng, Project Leader, ADC, TOT BIOPHARM, China

16:00
End of Conference Day 1

Day 2: 4 November 2020


Novel Advances In CLD Techniques & Technology


13:00
Chairperson’s Opening Remarks

Eric Chang, Head, Cell Line Development, JHL Biotech, China

13:00
Next-Generation Cell Line Development with Accelerated Timeline and High Productivity

  • Cell line development strategy for accelerated Covid-19 program approval
  • Codon impact on productivity
  • Next-generation sequencing application in cell line development

Zheng Zhang, Director II, Cell Line Development, WuXi Biologics, China

13:30
Single Cell Confidence – Creating the Double Lock of Assurance

Mark Stockdale, Amalgamator of Business and Biology, Solentim, UK

14:00
Using Recombinant Insulin in DoE for Media Development

  • Case study
  • Insulin – CHO Mab
  • Insulin – HEK293 Influenza Virus

Chantale Julien, Global Product Manager, Novo Nordisk Pharmatech, Denmark

14:30
Online Networking & Stretch Break

15:00
Difficult-to-Express Proteins Benefitting From Human Cells as a Production System

Dr. Vicky Goralczyk, Director, Cell Line and Bioprocess Development, Glycotope, Germany  

15:30
Next-Generation Cell Line Development Platform for Advanced Bispecific Antibodies Expression

Dr. Séverine Fagète, Vice President, Cell Line Development Services, Selexis, SA, Switzerland

16:00
End of Conference Day 2

Day 3: 5 November 2020


Biomanufacturing 2030 – China’s Great Leap


13:00
Scaling Up the Commercial Production of mAb Therapeutics in China

  • China’s capacity outlook and how do we capitalize on the mAb therapeutics markets
  • Teruisi’s breakthrough of mAb’s tech transfer and large-scale production in China while in-line with international standards – challenges and key learnings
  • Manufacture showcase to improve cost and efficiency

Dr. Wu You Ling, Chief Executive Officer, Zhejiang Teruisi Pharmaceuticals, China

13:30
Build vs. Buy – Long-term View of Capacity, Supply-Demand Balance and Investment in China’s Manufacturing Facilities

  • Insights on biopharma market segments driving new growth and where is the supply and demand
  • Identifying new market for biomanufacturing – emerging locations and site selection strategy
  • Manufacturing capacity outlook – utilization rates, new investment and a medium-term position
  • Commercial phase market outlook for CDMOs in China

Fireside Chat:
Jeff Li, General Manager, Lonza Pharma Biotech and Nutrition, China
Kevin Yang, Vice President, CMC and Manufacturing, I-MAB Biopharma, China

14:00
Online Networking & Stretch Break


Future Facilities & Smart Biomanufacturing


14:30
Tools and Best Practices for Successful Technology Transfer

Mahalia Corrales, Senior Director, Process Development & Technology, JHL Biotech, Taiwan

15:00
Manufacturing Technology Showcases – Improving Cost and Efficiency

  • Next gen manufacturing facilities design and investment trends
  • Smart automation case studies to increase facility efficiency and cost optimization
  • Intelligent bioreactors – advantages and benefits

Frank Ye, Senior Vice President, Technical Operations, Transcenta, China

15:30
Biomanufacturing Process Validation and Quality Risk Management

  • New process concepts of CQAs, CPPs, and QbDs
  • Best practices on quality risk management in bioprocess development
  • Case study on Bio-Thera’s manufacturing process quality control on the newest Humira biosimilar

Bao Cai, Senior Director, Manufacturing, Bio-Thera Solutions, China

16:00
End of Conference Day 3

Day 1: 3 November 2020

13:00
Chairperson’s Opening Remarks

Chen Guang, Consultant, Agency for Science, Technology and Research (A*STAR), Singapore


Joint Opening Plenary


13:10
Keynote Address:
China’s Big Leap towards BioPharma 2030  Innovation, Industrialization, Internationalization

Dr. Song Ru Lin, Executive President, China Pharmaceutical Innovation and Research Development Association (PhIRDA), China

13:30
Venture Capitals’ Roundtable:  
Show Me the Drug

  • Investment landscape in the Chinese biopharma market
  • Evaluating drug pipelines and development prospects
  • Mergers, expansion and JVs – Where do we see transactions picking up?
  • Financing new plants, new therapeutics, product launch and scaling-up operations – How do we review?
  • Manufacturing 4.0 – How do VCs and banks play a part in modernising the value chain?

Moderator:
Judith Li, Partner, Lilly Asia Ventures, China

Panelists:
Rani Jarkas, Chairman, Cedrus Group, Hong Kong
Lynn Yang, Managing Director, Sequoia Capital, China
Michael Xue, Managing Director, Morningside Ventures, China

14:15
Industry Spotlight:
Addressing Complex Protein Challenges with Lonza’s GS Xceed® Toolbox

Dr. Allison Porter, Head of Expression System Sciences, Lonza Pharma & Biotech, U.K.

14:45
Online Networking & Stretch Break


End of Joint Opening Plenary and 2nd Cell & Gene Therapy Manufacturing commences

China Market


15:00
Chairperson’s Opening Remarks

15:00
Case Study: Tumor-infiltrating Lymphocyte Development

  • Development of potential candidates
  • Managing China’s cell therapy landscape

Liu Yarong, Chief Executive Officer, Grit Therapeutics, China

15:30
The Case of Solid Tumors:
From Liquid to Solid Tumors, from Manual to Automatic Manufacturing

  • Product differentiation: solid tumor advantages
  • Overcoming challenges of targeting solid tumors

Dr Zhang Yu, Senior Vice President and Chief Scientific Officer, Vcanbio Cell&Gene Engineering, China

16:00
Chairperson’s Summary and End of Day 1

Day 2: 4 November 2020

13:00
Chairperson’s Opening Remarks

Shaheer Bardissi, Executive Board Member, Head of Gene and Cell Therapy, Minapharm Pharmaceuticals, Egypt


Technology and Innovation


13:00
Cell and Gene R&D Strategy Showcase – A Case Study of Epigeneron

  • Therapeutic target discovery programs and the molecular diagnostics programs
  • Scientific and commercial breakthroughs of therapies
  • Japan’s cell and gene therapy market in glance

Hara Ryujiro, Head of R&D Strategy, Epigeneron, Inc, Japan

13:40
Technical Showcase: Treating Solid Tumors with TCR-T Therapy

  • Generation of TCR T11.8-10-17 by HLA-A*02 allogenic priming approach
  • Tumor cell recognition assay for efficacy safety
  • Parallel studies using retroviral and lentiviral SIN systems

Liu Jingxian, TCR Discovery and Early Development, Cytovant Sciences, China

14:10
Online Networking and Stretch Break

14:40
Accelerating CAR-T Development and Manufacturing

  • Understanding and assessing manufacturability
  • Addressing the cost problem and solutions
  • Chemistry, Manufacturing, and Controls (CMC) case study
  • Product enhancement, innovation and technology

Dr Yao Shuyuan, VP of Operations, Wuxi AppTec and General Manager, Wuxi ATU, China

15:00
World’s First off-the-shelf NK Cell-based Immunotherapy in the Fight Against Cancer

Troels Jordansen, CEO, Glycostem Therapeutics, Netherland

15:40
Indonesia Case Study: Developing UC Stem Cells for COVID-19

  • Challenges in supply chain management
  • Working with small group trials

Sandy Qlintang, Deputy Director, PT Kalbe, Indonesia

16:20
Chairperson’s Summary and End of Day 2

Day 3: 5 November 2020

13:00
Chairperson’s Opening Remarks


Investments and Commercialisation


13:00
Biotech Investors’ Roundtable: Financial Incentives, Investments and Pricing 

  • Pricing, investment and making the therapies affordable
  • Post COVID-19 investment climates
  • Commercial models
  • Market access, and reimbursement models

Moderator:
Rohit Kulkarni, Vice President, Stem Cell Society of India, India

Panelists:
Kan Chen, Principal, Qiming Weichuang Venture Capital Management, China
Paolo Morgese, Director for EU Market Access and Member Relations, Alliance for Regenerative Medicine, Switzerland
Shaheer Bardissi, Executive Board Member, Head of Gene and Cell Therapy, Minapharm Pharmaceuticals, Egypt

13:50
Access to advanced therapies in Europe and sector outlook

  • Scenarios of EMA approvals and market access
  • Pricing mechanisms
  • European market outlook for treatment
  • CART-T and regenerative market commercial potential

Paolo Morgese, Director for EU Market Access and Member Relations, Alliance for Regenerative Medicine, Switzerland

14:30
Introducing Advanced Therapies into Emerging Countries: A Case Study

  • Availability and affordability
  • Challenges associated to opportunities
  • An integrated model for innovation and affordability

Shaheer Bardissi, Executive Board Member, Head of Gene and Cell Therapy, Minapharm Pharmaceuticals, Egypt

15:10
Chairperson’s Summary and End of Day 3